News of Note—Takeda grabs approval, repackager recalls 40 lots of losartan

Woman typing on computer
(Max Pixel CC0)

> Drug repackager Legacy Pharmaceutical Packaging is recalling 40 repackaged lots of Losartan Tablets USP 25 mg, 50 mg and 100 mg to the consumer level because they were made with an API in which the impurity N-Nitroso N-Methyl 4-amino butyric acid was detected. Release  

> Cambrex has completed an update at its R&D lab in Milan, including the installation of a 12,000-liter reactor into one of its cGMP manufacturing facilities at the site. Release

> CDMO Ajinomoto Bio-Pharma Services  is adding a new fully isolated, nested flexible fill line, installing automated packaging and labeling equipment and upgrading its continuous flow and small molecule API manufacturing capabilities at a plant in San Diego as part of a $100 million  investment in its manufacturing network. Release

> The FDA has approved a submission from Takeda to produce Flexbumin human albumin solution at the $1 billion plant in Covington, Georgia, that it picked up in its buyout of Shire. Report

Suggested Articles

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.

Taro Pharmaceuticals has recalled two lots of a seizure drug because of suspension issues.

Sanofi will unload six manufacturing sites and 3,100 employees into a new API production company as it looks for €2 billion in cost savings.